Head-to-head · WeighScore
Cost Plus Drugs vs Maves
The verdict
Maves takes it — 71.8/100 to 58.5/100.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cost Plus Drugs | Maves |
|---|---|---|
| WeighScore | 58.5/100 | 71.8/100 |
| Grade | C | C |
| Scorecard rank | #370 | #89 |
| Semaglutide | $279/mo (brand Ozempic) | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #370 · C
Strengths
- Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
- Around $279/mo for branded Ozempic — well below typical retail list prices
- Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
- Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
- Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing
Where it loses points
- Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
- Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
- Wegovy availability has been spotty — check current stock before assuming it ships
- No compounded semaglutide or tirzepatide — brand only
- No clinical follow-up — side-effect monitoring falls to your prescribing clinician
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.